Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.

Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: A transdermal delivery system of drug and a method of preparing the same are provided. More specifically, the invention can be a transdermal delivery system applied for various protein drugs such as vaccines and chemical drugs, because the drug delivery system has a biocompatibility, biodegradation property, transdermal delivery property, the safety of human body, maximum activity of protein drugs, good bio-conjugation efficiency and a long-term efficacy, a method of preparing the same and its use.

Abstract: Provided herein is an analytical method for determining whether a hepatocellular carcinoma patient has susceptibility or resistance to sorafenib treatment by analyzing the mRNA expression of FGFR1, optionally along with the mRNA expressions of other biomarkers (i.e., VEGFR2, PDGFR?, c-KIT, c-RAF, EGFR, and/or mTOR) to select a patient having susceptibility to sorafenib treatment and a patient having resistance to sorafenib treatment before employing molecular targeted therapy with sorafenib.

Abstract: The present invention relates to a method for predicting sensitivity to treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors, by using a biomarker. An effective means and anticancer therapy for cancer treatment of liver cancer are selected by predicting the effect of treatment with VEGFR inhibitors on liver cancer patients through the present invention, thereby increasing the treatment effect and minimizing the side effects of liver cancer treatment.

Abstract: The present invention relates to a method for predicting sensitivity to treatment with a vascular endothelial growth factor receptor (VEGFR) inhibitor. According to the present invention, effects on the treatment of liver cancer patients with a vascular endothelial growth factor receptor (VEGFR) inhibitor are predicted. Based on the prediction, an effective means and anticancer therapy for treatment of liver cancer are selected, thereby increasing treatment effects and minimizing the side effects of liver cancer treatment.

Abstract: Provided herein is an analytical method for determining whether a hepatocellular carcinoma patient has susceptibility or resistance to sorafenib treatment by analyzing the mRNA expression of FGFR1, optionally along with the mRNA expressions of other biomarkers (i.e., VEGFR2, PDGFR?, c-KIT, c-RAF, EGFR, and/or mTOR) to select a patient having susceptibility to sorafenib treatment and a patient having resistance to sorafenib treatment before employing molecular targeted therapy with sorafenib.

Abstract: A transdermal delivery system of drug and a method of preparing the same are provided. More specifically, the invention can be a transdermal delivery system applied for various protein drugs such as vaccines and chemical drugs, because the drug delivery system has a biocompatibility, biodegradation property, transdermal delivery property, the safety of human body, maximum activity of protein drugs, good bio-conjugation efficiency and a long-term efficacy, a method of preparing the same and its use.